Overview

Deepcell focuses on biotechnology, specifically in cell analysis and sorting through its REM-I platform. This platform uses label-free imaging, deep learning, and microfluidics to analyze and categorize cells based on their shape and structure, providing detailed data for researchers. Unlike competitors, Deepcell combines these technologies to offer comprehensive insights that are particularly useful for pharmaceutical companies and academic researchers. The company's goal is to enhance cell analysis capabilities, helping clients gain valuable insights into cellular behavior and disease mechanisms.

Simplify's Take

What believers are saying

• Deepcell is raising $80M to expand and accelerate product development.
• Demand for label-free imaging technologies is increasing, aligning with Deepcell's offerings.
• AI in translational research is expanding, enhancing Deepcell's value proposition.

What critics are saying

• Emerging competition from companies like Berkeley Lights could impact Deepcell's market share.
• Rapid technological advancements may require costly updates to Deepcell's REM-I platform.
• Potential ethical concerns and regulatory scrutiny could slow product adoption.

What makes Deepcell unique

• Deepcell's REM-I platform combines label-free imaging with deep learning for cell analysis.
• The company uses advanced microfluidics for precise cell sorting and analysis.
• Deepcell's AI-driven technology provides high-dimensional quantitative readouts of individual cells.

Help us improve and share your feedback! Did you find this helpful?

YesNo

Funding

Total Funding

$178M

Above

Industry Average

Funded Over

4 Rounds

Notable Investors:

Andreessen Horowitz

Notable Investors:

Andreessen Horowitz

$80,000,000

Late VC

Oct 2022

Late VC funding comparison data is currently unavailable. We're working to provide this information soon!

Late VC Funding Comparison

Coming Soon

View all funding stages